Elekta completes its investment in ViewRay

STOCKHOLM, December 6, 2019 – Elekta AB (EKTA-B.ST) announced today that that it has completed its investment in ViewRay, Inc. (Nasdaq:VRAY), which was announced on December 2, 2019. 

Elekta has invested USD 36 M for 11,501,597 shares of common stock of ViewRay, corresponding to approximately 7.6 percent of the outstanding common stock in ViewRay on a fully diluted basis in the underwritten public offering. The price was set at USD 3.13 per share, pursuant to the Elekta’s commitment agreement with ViewRay.

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Public Affairs
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com  
Time zone: CET: Central European Time

Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: Cecilia.Ketels@elekta.com
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 22:02 CET on December 6, 2019. (REGMAR)

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.